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Tramadol and meperidine are both synthetic
phenylpiperidine-derivative opiate agonists. They
are strong analgesics used in the relief of moder-
ate to severe pain. Tramadol has adverse effects
such as dry mouth, constipation, urinary retention,
visual disturbance, and confusion. Meperidine
has been observed to have clinical manifestations
of central nervous system (CNS) stimulation such
as seizures, agitation, irritability, disorientation,
nervousness, tremors, twitches, and myoclonus.1
These effects may be related to serum levels of
meperidine and its active metabolite normeperi-
dine.2 Opioids can increase muscle tone and may
cause muscle rigidity. Opioid-induced rigidity is
probably related to a catatonic state, which can
be induced by opioids.3
Catatonic features can be observed in a sub-
type of schizophrenia, major depressive disorder,
and bipolar disorder. Catatonia may also be caused
by a variety of medical or surgical conditions, such
as neoplasms, encephalitis, head trauma, diabetes,
and other metabolic disorders. Its clinical mani-
festations include motor immobility, excessive
motor activity, extreme negativism or mutism,
peculiarities of voluntary movement, echolalia,
and echopraxia. In addition, medications, such
as antipsychotics, could induce catatonia.4
fDelirium is characterized by a disturbance o
consciousness and a change in cognition or de-
velopment of a perceptual disturbance. The dis-
turbance develops over a short period of time and
tends to fluctuate during the course of the day.
Associated clinical features of delirium include
sleep-wake cycle disturbance, disturbed psychomo-
tor behavior, and emotional disturbance. Depend-
ing on the etiology, delirium can be associated
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CASE REPORT
with many nonspecific neurologic abnormalities
such as tremor, myoclonus, asterixis, and reflex or
muscle tone changes.5 A diminution in choliner-
gic function—an excess of dopamine, norepi-
nephrine, and glutamate—and disturbances in
serotonergic and γ-aminobutyric acid activities
have been implicated in its pathogenesis.6
We report a patient who developed delirium
and catatonic features following coadminis-
tration of tramadol and meperidine. We also re-
view related articles and discuss the possible
pathophysiologies.
Case Report
In May 2005, a 39-year-old woman was diag-
nosed with gastric mucosa associated lymphoid 
tissue lymphoma (MALToma), stage III. She suf-
fered from abdominal pain and dysphagia, at
first, in March 2005. She underwent chemother-
apy with cyclophosphamide 1000 mg, epirubicin
hydrochloride 100 mg, vincristine sulfate 2 mg,
and prednisolone 100 mg shortly after the diag-
nosis. She received pantoprazole, amoxicillin,
clarithromycin, lamivudine, and prednisolone
after chemotherapy. However, 1 week later, she
visited our emergency department because of ab-
dominal pain. Meperidine 50 mg was injected
for pain. One hour later, irritable mood, restless-
ness, and derealized sensation were noted. Five
minutes after injection, the symptoms were re-
mitted spontaneously. Then, she was admitted to
our medical ward for further evaluation. Panto-
prazole 40 mg and tramadol 150 mg daily were
prescribed with intravenous route. Two days
later, meperidine 25 mg was injected addition-
ally for her pain around 9 am. Two hours later,
she stated that her hands and feet did not belong
to her. The patient had confused consciousness,
irritable mood, and inappropriate grasping be-
haviors around 1 pm. She reported seeing a man
on the wall and many spiders around her bed. At
3 pm, she claimed that she was dead and did not
know why her husband could see her. She could
walk to the toilet for urination with fair gait at
that time. Then, she developed mutism, immobile
standing beside her bed, refusal to sit down, and
reluctance to undergo physical examinations. She
rstood still throughout that night. The duty docto
stopped all the medications. The results of neu-
rologic examinations revealed isocoric pupil, posi-
tive bilateral light reflex, no obvious facial palsy,
symmetric limbs muscle power, and normal deep
tendon reflex. Next day, stupor consciousness,
inattention, mutism, fixed posture, and negativism
were still observed. Tracing back her history, there
was no head trauma, epilepsy, and no overt psy-
chiatric features. During the period of catatonia,
the laboratory data showed normal findings in
complete blood count, electrolytes, renal function,
and liver function. Brain image and electroen-
cephalographic examinations were not performed
due to the absence of obvious focal signs.
On the morning of the 3rd day, she woke up
cand spoke to others spontaneously. All catatoni
t features had disappeared. The patient did no
receive any psychotropic during those 2 days. She
twas discharged 2 days later, and followed up a
our hematology department afterwards.
Discussion
At the emergency department, the patient devel-
roped irritable mood and derealization lasting fo
5 minutes after injection of meperidine 50 mg.
However, following admission, the full symptoms
of delirium and catatonia in this patient occurred
twith a lower dose meperidine (25 mg) subsequen
to the treatment of tramadol and pantoprazole.
gIt suggests that the symptoms are related to a dru
interaction. Pantoprazole, a proton-pump in-
hibitor, is mainly metabolized by cytochrome
P-450 2C19 (CYP2C19).7 cTramadol is a syntheti
4-phenylpiperidine. O-demethylation and N-
demethylation are two main metabolic pathways
of tramadol.8 cAs to meperidine, its main metaboli
pathway is N-demethylation.9 There is no case
report about pantoprazole-induced or tramadol-
tinduced delirium and catatonia on MEDLINE, bu
there is one case report of meperidine-induced
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delirium.10 The complete CYP P450 enzyme infor-
mation of pantoprazole, tramadol, and meperi-
dine is not available, and so the pharmacokinetic
interaction of these drugs cannot be concluded.
Some overlaps of metabolic pathways are noted
between tramadol and meperidine. Tramadol and
meperidine are both synthetic opioid compounds
in the group of phenylpiperidine series. According
to available data and pharmacologic action of
these three agents, we speculate that the etiologies 
of delirium and catatonia in this patient were
probably related to tramadol and meperidine,
and less likely to be related to pantoprazole.
Pharmacodynamic explanations of catatonia
involve the dopamine system in the basal gan-
glia,4 serotonin system,11 and γ-aminobutyric acid
(GABA) system.12 Northoff et al13 reported that
dopaminergic metabolites in the plasma of acute
catatonic patients were increased. These results
suggest hyperactivity in the dopaminergic system
in catatonia. However, hypoactivity in this system
was also assumed.4 In addition to the dopamine
system, Lauterbach12 reported that serotonergic
drugs could induce catatonic syndrome because
of increased 5-HT1A receptor stimulation and
GABAb receptor stimulation. Tramadol and
meperidine are not only anticholinergic agents
but also potent inhibitors of serotonin reuptake
into presynaptic neurons.14,15 Based on the find-
ings of our case, we speculate two possible 
mechanisms of catatonia. First, dopamine and
acetylcholine have a reciprocal relationship in
the nigrostriatal pathway. A balance between the
dopaminergic and cholinergic system is neces-
sary for controlling voluntary movement.16 Anti-
cholinergic effects of these two medications may
result in an imbalance between these two systems.
Second, serotonergic activity may be related to
catatonia.17,18 This model could also explain the
catatonic features in this patient.
Fogarty and Murray1 reported a patient who
developed agitation and visual hallucinations
after using meperidine 930 mg daily for 4 days.
Psychiatric symptoms, including anxiety, fearful-
ness, and hypervigilance, resolved over the next
12 hours after meperidine was discontinued.
Eisendrath et al10 reported six cases of meperidine-
induced delirium. Their daily doses of meperidine
ranged from 225 to 1400 mg. In our case, the pa-
tient’s delirium was noted 4 hours after a single
fdose (25 mg) of meperidine. Before injection o
meperidine, our patient had regularly received
tramadol 150 mg daily. From the pharmacody-
ynamic aspect, the etiology of delirium was highl
related to the anticholinergic effect of tramadol
and meperidine.17,18 The CNS receptor level’s
yinteraction of opioids and their metabolites ma
contribute to the pathogenesis of delirium. More-
over, the patient’s anticancer drugs, cyclophospha-
mide and prednisolone, can also cause delirium
because of their strong anticholinergic effects.
Unfortunately, there is no clear support for a
diagnosis of delirium such as cognitive examina-
ftion or thorough assessment of a broad range o
cdelirium symptoms as in the use of a specifi
symptom rating scale over time. These could be
ictal symptoms (complex partial, even confusional
status) perhaps associated with some CNS lesions
including meningeal lymphoma, yet neither an
electroencephalogram nor magnetic resonance
imaging was done in this at-risk patient. Further,
ythere is the possibility that this episode was onl
fcoincidentally related in time to the injection o
fmeperidine. A design with another injection o
meperidine following recovery could strengthen
the association to this drug with increased causal-
ity. In addition, the diagnosis of delirium can be
verified with an electroencephalographic exami-
nation or physostigmine injection test.
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